Sergey Sergeevich Kulikov launched Ageo Product Line (APL) in 2011, claiming European origins under Cyprus law while operating from Kazakhstan. The company's website lists a Delaware address, which belongs to IncServ, a corporate formation service, suggesting a US presence in name only. Kulikov's VKontakte profile, however, specifies Moscow, Russia, as his corporate address, indicating a complex, multi-jurisdictional setup.
The decision to incorporate a US shell company, despite its primary operations being elsewhere, likely aims for regulatory arbitrage. Kulikov's personal narrative suggests he started APL to combat "injustice and unfairness" after a negative experience with an unnamed MLM where he claims senior management stripped him of his downline at age 17.
APL markets a range of health supplements and personal care items. Its flagship product line features "Accumullit SA Technology," which purportedly delivers vitamins through drops instead of traditional pills. These drops carry three-letter codes, such as ALT for allergies at €63.75 per packet, and GRW for immunity and youth at €42.50. NRM drops, priced at €42.50, are advertised to block diabetes development and reduce disease risk tenfold. PWR offers a his-and-hers duo for reproductive health, also €42.50, while FIT day and night drops combat weight gain for the same price. Each packet appears to contain 12-15 drops, though APL's materials do not specify the exact count.
Beyond the drops, APL's catalog includes dental care products, various teas, jelly drinks, muesli bars, coffee, oatmeal, and a cosmetics line. The company also offers an "Extravaganza" fragrance range, featuring twenty different scents, each priced at €42.50.
The compensation plan for APL affiliates directly ties earning potential to initial investment. New members must place a 100 PV (Personal Volume) product order to join. Maintaining commission eligibility requires a minimum 40 PV monthly order. The plan outlines ten ranks, from Affiliate to Crown Ambassador, with higher ranks demanding hundreds of thousands or millions in monthly group volume.
Recruitment commissions range from 10% to 20% on a new affiliate's first order. A 100 PV signup pays the recruiter 10%, while a 3000 PV signup yields 20%. Subsequent orders from personally recruited affiliates pay a flat 5%. Residual commissions operate on a binary structure, paying 15% to 30% on the weaker leg's weekly volume. The percentage depends on the affiliate's initial order size: a 200 PV signup earns 15%, but a 3000 PV signup gets 30%. A unilevel component pays 5% to 10% across six levels, with an Infinity Bonus available from level seven for higher ranks. APL's own compensation materials explicitly state: "The more you invest the more you get," noting that a 3000 PV order provides "a set of privileges" and enables "achieving great success."
APL does not distinguish between retail customers and affiliates. Anyone who purchases APL products is classified as an affiliate, meaning the company lacks genuine retail sales. This structure identifies APL as a product-based pyramid scheme, where commissions are earned on downline product purchases rather than external retail transactions.
The company makes aggressive medical claims for its products without apparent regulatory approval or scientific backing. For example, the NRM drops, which claim to block diabetes and reduce disease risk, rely on "folk medicine" ingredients like pitahaya and garcinia cambodian. Kulikov's biography does not indicate medical training, though he holds a patent for the "Accumullit SA Technology." Since APL presents itself as a US corporation through its Delaware incorporation, it falls under the purview of US Food and Drug Administration (FDA) regulations. The use of a US shell corporation likely exploits gaps in regulatory cooperation between the US and countries like Russia.
The pay-to-play model within APL means income potential directly correlates with an individual's initial spending, not their ability to sell products to retail customers. A legitimate multi-level marketing company bases earning potential on acquiring retail customers. APL's growth depends entirely on continuous recruitment. When recruitment slows, the scheme inevitably collapses, ensuring that most participants lose money.
APL later rebranded as APLGO and launched operations in the United States in October 2020.